Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Torsades de pointes induced by erythromycin

B Gitler1, L S Berger, S D Buffa

  • 1Department of Medicine, New Rochelle Hospital Medical Center, NY.

Chest
|February 1, 1994
PubMed
Summary

Intravenous erythromycin lactobionate can cause torsades de pointes, a dangerous heart arrhythmia. Physicians should be aware of this risk, especially when other causes are absent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aborted sudden death in a young male.

Postgraduate medical journal·2003
Same author

Commentary to praxis paper.

American journal of psychotherapy·2002
Same author

Psychotherapy, biological psychiatry, and the nature of matter: a view from physics.

American journal of psychotherapy·2001
Same author

Praxis as a radical alternative to scientific frameworks for psychotherapy.

American journal of psychotherapy·2000
Same author

Swan to phoenix: the metamorphosis.

Heart & lung : the journal of critical care·1998
Same author

Swan-Ganz catheter: misconceptions, pitfalls, and incomplete user knowledge--an identified trilogy in need of correction.

Heart & lung : the journal of critical care·1998

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Erythromycin lactobionate is increasingly used clinically.
  • Torsades de pointes is a potentially fatal cardiac arrhythmia.
  • Identifying drug-induced arrhythmias is crucial for patient safety.

Observation:

  • Two patients developed torsades de pointes following intravenous erythromycin lactobionate administration.
  • No other known causes for the arrhythmia were present in these patients.
  • A review of existing literature revealed similar case reports.

Findings:

  • Erythromycin lactobionate administration was temporally linked to torsades de pointes in observed cases.
  • Evidence suggests erythromycin can affect cardiac electrophysiology, potentially leading to arrhythmias.
  • This complication may be underrecognized in clinical practice.

Implications:

  • Healthcare providers must be vigilant for torsades de pointes in patients receiving erythromycin lactobionate.
  • Awareness of this adverse effect is critical for preventing serious cardiac events.
  • Further research into erythromycin's cardiac effects may be warranted.

Related Experiment Videos